{
    "clinical_study": {
        "@rank": "25218", 
        "arm_group": [
            {
                "arm_group_label": "Anti-thrombin III", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to test whether the administration of ATIII during the\n      intra-operative period results in improved anticoagulation for cardiopulmonary bypass (CPB)\n      and an attenuation of the activation of the coagulation cascade, as represented by a\n      decrease in fibrin degradation products. The investigators believe this benefit would extend\n      into the post-operative period resulting in a decreased incidence of thrombosis generation,\n      as represented by a decrease in fibrin degradation products in the ICU period."
        }, 
        "brief_title": "Anti-thrombin III (ATIII) vs Placebo in Children (<6mo) Undergoing Open Congenital Cardiac Surgery", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "ATIII Deficiency", 
        "condition_browse": {
            "mesh_term": "Antithrombin III Deficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All patients less than 6 months of age going for cardiac surgery that will require\n             cardiopulmonary bypass (CPB) with a documented ATIII level below 70%\n\n        Exclusion Criteria:\n\n          -  Less than 2.5kg\n\n          -  Known or suspected hereditary ATIII deficiency (family history of venous thrombosis\n             with decreased plasma levels of ATIII and no other potential causes of acquired\n             decreased ATIII)\n\n          -  On Ecmo (extracorporeal membrane oxygenation ) at time of surgery\n\n          -  Known history of thrombosis\n\n          -  Renal failure as described by the pediatric RIFLE criteria\n\n          -  H/o intracranial hemorrhage\n\n          -  Prematurity less than 37 weeks estimated gestational age\n\n          -  Previously diagnosed pro-thrombotic or hemorrhagic disorder\n\n          -  Prior ATIII supplementation\n\n          -  Prior therapeutic anticoagulant use"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "6 Months", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02103114", 
            "org_study_id": "Pro00051186"
        }, 
        "intervention": [
            {
                "arm_group_label": "Anti-thrombin III", 
                "description": "If the Activated clotting time (ACT) is below the goal of 480 seconds the patient will first be given an additional dose of 200u/kg of heparin. If the patient's ACT remains below 480 seconds, they will be given 20ml/kg of FFP. The above dose of heparin and FFP will be repeated until an ACT of greater than 480 seconds is achieved.\nIf Preoperative ATIII functional assay level is less than 70% - patients would be enrolled and randomized to either Placebo (normal saline) or ATIII.  Intraoperatively- (correcting to 100%) according to the following formula:\nUnits required = ((100%- baseline ATIII level*%) X body weight)/1.4\nexpressed as a % normal level based on functional ATIII assay", 
                "intervention_name": "Anti-thrombin III", 
                "intervention_type": "Drug", 
                "other_name": "Thrombate III"
            }, 
            {
                "arm_group_label": "Anti-thrombin III", 
                "description": "Normal saline placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Thrombin", 
                "Antithrombin III", 
                "Antithrombin Proteins", 
                "Antithrombins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 3, 2014", 
        "location": {
            "contact": {
                "email": "angelo.porto@dm.duke.edu", 
                "last_name": "Angelo Porto", 
                "phone": "919-613-0469"
            }, 
            "contact_backup": {
                "email": "narai.balajonda@duke.edu", 
                "last_name": "Naraida Balajonda", 
                "phone": "919-681-4377"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27708"
                }, 
                "name": "Duke University"
            }, 
            "investigator": {
                "last_name": "Edmund H Jooste, M.B, Ch.B.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double Blind Randomized Placebo-controlled Study in Children (<6mo) Comparing the Effects of Anti-thrombin III (ATIII) or Placebo on the Coagulation System in Infants With Known Low ATIII Levels Undergoing Open Congenital Cardiac Surgery", 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Edmund Jooste, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the mean and SD (Standard Deviation) of the Calibrated Automated Thrombography (CAT) measurements of the control and ATIII groups at Time 4 (just prior to termination from CPB approximately 5 to 15 minutes prior to CPB termination ).", 
            "measure": "Decreased activation of the coagulation and fibrinolytic systems", 
            "safety_issue": "No", 
            "time_frame": "Time 4 (just prior to termination from CPB)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02103114"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the mean and SD of the Calibrated Automated Thrombography (CAT) measurements of the control and ATIII groups at times Time 3 (10min to 30min after initiation of CPB), Time 5-Time 7 (ICU arrival to Post OP Day 4)", 
                "measure": "Decreased activation of the coagulation and fibrinolytic systems", 
                "safety_issue": "No", 
                "time_frame": "After initiation of bypass (Time 3), and ICU arrival (Time 5) to Time 7 (Post OP Day 4)"
            }, 
            {
                "description": "Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the mean and SD of the ATIII (functional assay), D dimer and TEG measurements of the control and ATIII groups at Time 3-Time 7 (10min to 30min after initiation of CPB to Post OP Day 4).", 
                "measure": "Decreased activation of the coagulation and fibrinolytic systems", 
                "safety_issue": "No", 
                "time_frame": "After initiation of bypass (Time 3) to Time 7 (Post OP Day 4)"
            }, 
            {
                "description": "Total dose of heparin and protamine", 
                "measure": "Total dose of heparin and protamine", 
                "safety_issue": "No", 
                "time_frame": "Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)"
            }, 
            {
                "description": "Total volume of blood products exposed intraoperatively including the pump prime (ml/kg)", 
                "measure": "Total volume of blood products", 
                "safety_issue": "No", 
                "time_frame": "Baseline (intraoperatively) (Time 1) to before termination of bypass (Time 4)"
            }, 
            {
                "description": "Time from protamine administration to skin dressing", 
                "measure": "Time from protamine administration to skin dressing", 
                "safety_issue": "No", 
                "time_frame": "Baseline (intraoperatively) (Time 1) to before termination of bypass (Time 4)"
            }, 
            {
                "description": "Volume of postoperative blood loss from 10min post protamine administration to 24 hour post protamine administration- (ml/kg)", 
                "measure": "Volume of postoperative blood loss", 
                "safety_issue": "No", 
                "time_frame": "From 10min post protamine administration to 24 hour post protamine administration"
            }, 
            {
                "description": "Volume of packed Red blood cell, Fresh frozen plasma and cryoprecipitate transfused (ml/kg) from start of surgery to 24 hours post protamine administration", 
                "measure": "Volume of blood products", 
                "safety_issue": "No", 
                "time_frame": "From start of surgery to 24 hours post protamine administration"
            }, 
            {
                "description": "Incidence of the use of rescue recombinant factor VIIa", 
                "measure": "Use of recombinant factor VIIa", 
                "safety_issue": "No", 
                "time_frame": "Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)"
            }, 
            {
                "description": "Study the safety profile of dosing the ATIII by monitoring the incidence of ECMO support within 24 hours postoperatively.", 
                "measure": "Safety profile of ATIII dosing", 
                "safety_issue": "No", 
                "time_frame": "Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)"
            }, 
            {
                "description": "Length of post operative ventilation", 
                "measure": "Length of post operative ventilation", 
                "safety_issue": "No", 
                "time_frame": "ICU arrival (Time 5) to Time 7 (Post OP Day 4)"
            }, 
            {
                "description": "Study the safety profile of dosing the ATIII by monitoring the incidence of mediastinal exploration within 24 hours postoperatively", 
                "measure": "Safety profile of ATIII dosing", 
                "safety_issue": "No", 
                "time_frame": "Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)"
            }, 
            {
                "description": "Study the safety profile of dosing the ATIII by monitoring the incidence of thrombotic disease", 
                "measure": "Safety profile of ATIII dosing", 
                "safety_issue": "No", 
                "time_frame": "Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)"
            }, 
            {
                "description": "Study the safety profile of dosing the ATIII by monitoring the incidence of renal disease", 
                "measure": "Safety profile of ATIII dosing", 
                "safety_issue": "No", 
                "time_frame": "Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)"
            }, 
            {
                "description": "Study the safety profile of dosing the ATIII by monitoring the incidence of intracranial hemorrhage", 
                "measure": "Safety profile of ATIII dosing", 
                "safety_issue": "No", 
                "time_frame": "Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)"
            }, 
            {
                "description": "Study the safety profile of dosing the ATIII by monitoring the length of time to delayed sternal closure", 
                "measure": "Safety profile of ATIII dosing", 
                "safety_issue": "No", 
                "time_frame": "Baseline (intraoperatively) (Time 1) to Time 7 (Post OP Day 4)"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "Grifols Biologicals Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}